ENTRY       D10936                      Drug
NAME        Galcanezumab (USAN/INN);
            Galcanezumab (genetical recombination) (JAN);
            Galcanezumab-gnlm;
            Emgality (TN)
PRODUCT     EMGALITY (Eli Lilly and Company)
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGSSVKV SCKASGYTFG NYWMQWVRQA PGQGLEWMGA IYEGTGKTVY
            IQKFADRVTI TADKSTSTAY MELSSLRSED TAVYYCARLS DYVSGFGYWG QGTTVTVSSA
            STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTKTY TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEAAGGPSVF
            LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR
            VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN
            QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGN
            VFSCSVMHEA LHNHYTQKSL SLSLG
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCRASKDIS KYLNWYQQKP GKAPKLLIYY TSGYHSGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GDALPPTFGG GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H133-L214, H146-H202, H225-H'225, H228-H'228, H260-H320, H366-H424, H'22-H'96, H'133-L'214, H'146-H'202, H'260-H'320, H'366-H'424, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
REMARK      Therapeutic category: 1190
            ATC code: N02CD02
            Product: D10936<JP/US>
EFFICACY    Analgesic, Antimigraine, Anti-calcitonin gene related peptide (GCRP) antibody
  TYPE      Monoclonal antibody
COMMENT     Preventive treatment of migraine
TARGET      CALCA (CGRP) [HSA:796] [KO:K12332]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N02 ANALGESICS
               N02C ANTIMIGRAINE PREPARATIONS
                N02CD Calcitonin gene-related peptide (CGRP) antagonists
                 N02CD02 Galcanezumab
                  D10936  Galcanezumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antimigraine Agents
              Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
               Galcanezumab
                D10936  Galcanezumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               119  Miscellaneous
                1190  Miscellaneous
                 D10936  Galcanezumab (USAN/INN); Galcanezumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Circulatory system
                CALCA (CGRP)
                 D10936  Galcanezumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10936
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10936
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10936
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10936
DBLINKS     CAS: 1578199-75-3
            PubChem: 346930785
///
